Literature DB >> 29656800

Dopaminergic Disturbances in Tourette Syndrome: An Integrative Account.

Tiago V Maia1, Vasco A Conceição2.   

Abstract

Tourette syndrome (TS) is thought to involve dopaminergic disturbances, but the nature of those disturbances remains controversial. Existing hypotheses suggest that TS involves 1) supersensitive dopamine receptors, 2) overactive dopamine transporters that cause low tonic but high phasic dopamine, 3) presynaptic dysfunction in dopamine neurons, or 4) dopaminergic hyperinnervation. We review evidence that contradicts the first two hypotheses; we also note that the last two hypotheses have traditionally been considered too narrowly, explaining only small subsets of findings. We review all studies that have used positron emission tomography and single-photon emission computerized tomography to investigate the dopaminergic system in TS. The seemingly diverse findings from those studies have typically been interpreted as pointing to distinct mechanisms, as evidenced by the various hypotheses concerning the nature of dopaminergic disturbances in TS. We show, however, that the hyperinnervation hypothesis provides a simple, parsimonious explanation for all such seemingly diverse findings. Dopaminergic hyperinnervation likely causes increased tonic and phasic dopamine. We have previously shown, using a computational model of the role of dopamine in basal ganglia, that increased tonic dopamine and increased phasic dopamine likely increase the propensities to express and learn tics, respectively. There is therefore a plausible mechanistic link between dopaminergic hyperinnervation and TS via increased tonic and phasic dopamine. To further bolster this argument, we review evidence showing that all medications that are effective for TS reduce signaling by tonic dopamine, phasic dopamine, or both.
Copyright © 2018 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antipsychotics; Dopamine; Dopamine agonists; Hyperinnervation; Positron emission tomography; Tourette syndrome

Mesh:

Substances:

Year:  2018        PMID: 29656800     DOI: 10.1016/j.biopsych.2018.02.1172

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  21 in total

1.  Clinical applications of neurochemical and electrophysiological measurements for closed-loop neurostimulation.

Authors:  J Blair Price; Aaron E Rusheen; Abhijeet S Barath; Juan M Rojas Cabrera; Hojin Shin; Su-Youne Chang; Christopher J Kimble; Kevin E Bennet; Charles D Blaha; Kendall H Lee; Yoonbae Oh
Journal:  Neurosurg Focus       Date:  2020-07       Impact factor: 4.047

2.  Frequency and Intensity of Premonitory Urges-to-Tic in Tourette Syndrome Is Associated With Supplementary Motor Area GABA+ Levels.

Authors:  Jason L He; Mark Mikkelsen; David A Huddleston; Deana Crocetti; Kim M Cecil; Harvey S Singer; Richard A E Edden; Donald L Gilbert; Stewart H Mostofsky; Nicolaas A J Puts
Journal:  Mov Disord       Date:  2021-12-02       Impact factor: 9.698

3.  Gray matter abnormalities in Tourette Syndrome: a meta-analysis of voxel-based morphometry studies.

Authors:  Xinyue Wan; Simin Zhang; Weina Wang; Xiaorui Su; Jun Li; Xibiao Yang; Qiaoyue Tan; Qiang Yue; Qiyong Gong
Journal:  Transl Psychiatry       Date:  2021-05-14       Impact factor: 6.222

4.  Dopamine boosts intention and action awareness in Parkinson's disease.

Authors:  Steven Di Costa; Ewgenia Barow; Ute Hidding; Tina Mainka; Monika Pötter-Nerger; Carsten Buhmann; Christian K E Moll; Patrick Haggard; Christos Ganos
Journal:  Exp Brain Res       Date:  2020-06-27       Impact factor: 1.972

5.  Altered urinary tetrahydroisoquinoline derivatives in patients with Tourette syndrome: reflection of dopaminergic hyperactivity?

Authors:  Philipp Capetian; Veit Roessner; Caroline Korte; Susanne Walitza; Franz Riederer; Regina Taurines; Manfred Gerlach; Andreas Moser
Journal:  J Neural Transm (Vienna)       Date:  2020-12-23       Impact factor: 3.575

6.  Elevated Expression of SLC6A4 Encoding the Serotonin Transporter (SERT) in Gilles de la Tourette Syndrome.

Authors:  Mathis Hildonen; Amanda M Levy; Christina Dahl; Victoria A Bjerregaard; Lisbeth Birk Møller; Per Guldberg; Nanette M Debes; Zeynep Tümer
Journal:  Genes (Basel)       Date:  2021-01-12       Impact factor: 4.096

7.  Cocaine-Induced Changes in Tonic Dopamine Concentrations Measured Using Multiple-Cyclic Square Wave Voltammetry in vivo.

Authors:  Jason Yuen; Abhinav Goyal; Aaron E Rusheen; Abbas Z Kouzani; Michael Berk; Jee Hyun Kim; Susannah J Tye; Charles D Blaha; Kevin E Bennet; Dong-Pyo Jang; Kendall H Lee; Hojin Shin; Yoonbae Oh
Journal:  Front Pharmacol       Date:  2021-07-06       Impact factor: 5.810

Review 8.  Merging the Pathophysiology and Pharmacotherapy of Tics.

Authors:  Farhan Augustine; Harvey S Singer
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2019-01-09

Review 9.  Tourette syndrome research highlights from 2018.

Authors:  Olivia Rose; Andreas Hartmann; Yulia Worbe; Jeremiah M Scharf; Kevin J Black
Journal:  F1000Res       Date:  2019-07-01

10.  Association of Rare Genetic Variants in Opioid Receptors with Tourette Syndrome.

Authors:  Christel Depienne; Sorana Ciura; Oriane Trouillard; Delphine Bouteiller; Elsa Leitão; Caroline Nava; Boris Keren; Yannick Marie; Justine Guegan; Sylvie Forlani; Alexis Brice; Mathieu Anheim; Yves Agid; Paul Krack; Philippe Damier; François Viallet; Jean-Luc Houeto; Franck Durif; Marie Vidailhet; Yulia Worbe; Emmanuel Roze; Edor Kabashi; Andreas Hartmann
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2019-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.